Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis

Ulcerative Colitis Clinical Trial

Official title:

Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04882683
• Other study ID #: UCB-MNCs-UC-2021
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2021
• Est. completion date: December 31, 2022

Study information

• Verified date: May 2021
• Source: Shandong Qilu Stem Cells Engineering Co., Ltd.
• Contact: xueliang C Jiang
• Phone: +8615954103609
• Email: jiangxueliang678[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study conducted a systematic clinical observation of the clinical efficacy of UCB-MNCs in the treatment of hormone-resistant or hormone-dependent ulcerative colitis, in order to observe its clinical safety and efficacy.

Description:

This study adopts a randomized and controlled clinical research design. Patients are randomly divided into conventional treatment control group and UCB-MNCs treatment test group. The control group is given conventional treatment: prednisone combined azathioprine or adalimumab; the test group is given conventional treatment combined UCB-MNCs treatment, follow-up observations were carried out, in order to observe the clinical efficacy and safety of UCB-MNCs in the treatment of hormone resistance or hormone-dependent ulcerative colitis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 31, 2022
• Est. primary completion date: June 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• 1. Western medicine diagnosis is consistent with patients with refractory ulcerative colitis.

• 2. 18 Years to 65 Years,male or female.

• 3. Those who voluntarily participate in this clinical study and have signed an informed consent.

Exclusion Criteria:

• 1. Patients with non-refractory UC.

• 2. Those who are pregnant or breastfeeding, or have a childbirth plan in the near future.

• 3. People with severe allergies or allergies to known ingredients in basic treatments.

• 4. Patients with severe primary diseases such as severe cardiovascular and cerebrovascular diseases, liver and kidney, and hematopoietic system.

• 5. There are serious complications, such as local stenosis, intestinal obstruction, intestinal perforation, multiple intestinal polyps, toxic megacolon, rectal cancer, etc..

• 6. Patients with mental disorders and intellectual disabilities.

• 7. Patients who have participated in clinical studies of other drugs in the past 3 months.

• 8. Those who are seriously ill and need emergency treatment.

• 9. Patients who are still undergoing other treatment options for ulcerative colitis.

• 10. Researchers believe that it is not suitable for entry.

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis

Intervention

Drug:
• Prednisone
0.75 mg per kilogram per day for three months
• Azathioprine
1 mg per kilogram per day for three months
• Adalimumab
40mg every two weeks for three months

Biological:
• umbilical cord blood mononuclear cells
Peripheral intravenous infusion method, infusion of umbilical cord blood mononuclear cell suspension 50ml (cell number 2×10^8).

Locations

Country	Name	City	State
China	The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine	Shandong	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Shandong Qilu Stem Cells Engineering Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical efficacy rate	According to the method of modified Mayo score calculation, it is defined as a decrease of =30% of the score or a decrease of =3 points relative to the baseline value, and a decrease of =1 point or a score of 0 or 1 in the sub-item score of blood in the stool, and this type of patient is judged Effective for treatment. Clinical effective rate = (effective number of people / total number of people in this group ) × 100%.	Change from Baseline Clinical efficacy rate at 8th and 16th week, and the first week after the end of treatment.
Primary	Clinical response rate	According to the method of modified Mayo score calculation, it is defined as a score = 2 points and no single sub-item score> 1 point. Clinical remission rate =(number of remissions / total number of people in this group) × 100%.	Change from Baseline Clinical response rate at 8th and 16th week, and the first week after the end of treatment.
Secondary	Clinical symptom score	According to the scoring criteria for individual symptoms (diarrhea, mucus pus and blood in the stool, abdominal pain, tenesmus), the severity of symptoms is divided into 0, 2, 4, and 6 points. The higher the score, the more severe the symptoms.	Change from Baseline clinical symptom score at the first week after the end of treatment.
Secondary	Endoscopic response rate	According to the method of modified Mayo score, endoscopy found that the score decreased by at least 1 point from baseline. Endoscopic response rate = (number of endoscopic responders/total number of people in the group) × 100%.	Change from Baseline endoscopic response rate at the first week after the end of treatment.
Secondary	Mucosal healing rate	According to the method of modified Mayo score, the absolute score of the endoscopy discovery score is 0 or 1 point. Mucosal healing rate = (mucosal healing number / total number of people in this group) × 100%.	Change from Baseline mucosal healing rate at the first week after the end of treatment.